PCSK9 inhibition via base editing lowers LDL in patients with genetic high cholesterol

Genetic PCSK9 inhibition via base editing appeared safe and demonstrated dose-dependent, durable reductions in PCSK9 and LDL cholesterol, researchers reported.At the highest dose, VERVE-102 (Verve Therapeutics) was associated with an up to 88% reduction in PCSK9 and a 62% reduction in LDL, and could represent a single-dose, lifelong therapeutic to prevent atherosclerotic CVD in people with

venerdì 29 maggio 2026 New tab

May 29, 2026

2 min read

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

PCSK9 inhibition via base editing lowers LDL in patients with genetic high cholesterol

PCSK9 inhibition via base editing lowers LDL in patients with genetic high cholesterol

Other newsrooms on this story

Related reading

A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to…

So Far, So Good for PCSK9-Targeting Gene Therapy in Hypercholesterolemia

Gene-editing drugs are opening a new frontier in medicine

Bad cholesterol slashed 62% by single dose of gene-editing drug in small trial

One dose of gene-editing drug cut bad cholesterol 62% for months in small trial

Lilly reports new data on PCSK9 base editing gene therapy from Verve buyout

Related reading

A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to…

So Far, So Good for PCSK9-Targeting Gene Therapy in Hypercholesterolemia

Gene-editing drugs are opening a new frontier in medicine

Bad cholesterol slashed 62% by single dose of gene-editing drug in small trial

One dose of gene-editing drug cut bad cholesterol 62% for months in small trial

Lilly reports new data on PCSK9 base editing gene therapy from Verve buyout

Other newsrooms on this story